Type 2 Diabetes Mellitus (T2DM) Clinical Trial
Official title:
Randomized, Open-label, SU-controlled Study of 24-week Duration to Compare Metformin/Vildagliptin + Basal Insulin Versus Metformin/SU + Basal Insulin in T2DM Patients Starting Basal Insulin After Failing Metformin/SU
To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.
This study, conducted in T2DM patients failing a dual therapy with metformin/SU in whom the decision to start basal insulin has been taken, will compare vildagliptin+metformin versus the previously used SU+met combination (regimen kept unchanged) in association with basal insulin, up-titrated as per usual algorithms primarily based on FPG to obtain a similar improvement in glycemic control in both arms, on the incidence of hypoglycemic episodes over 24 weeks. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05102149 -
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
|
Phase 3 | |
Withdrawn |
NCT03423355 -
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
|
Phase 4 | |
Terminated |
NCT01923389 -
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
|
Phase 1 | |
Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05607160 -
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
|
||
Completed |
NCT05628090 -
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
|
||
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Completed |
NCT01002807 -
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
|
Phase 1 | |
Recruiting |
NCT04943861 -
Human Immunodeficiency Virus (HIV) Food Insecurities
|
N/A | |
Completed |
NCT02759107 -
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
|
Phase 1 | |
Completed |
NCT02643797 -
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
|
Phase 3 | |
Completed |
NCT05294458 -
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06327815 -
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
|
Phase 4 | |
Completed |
NCT02219646 -
Diabetes & Vardenafil
|
Phase 2 | |
Recruiting |
NCT05761301 -
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
|
Phase 1/Phase 2 | |
Completed |
NCT04504396 -
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
|
Phase 3 | |
Completed |
NCT01991093 -
Multiple Electrode Aggregometry & Clopidogrel Resistance
|
||
Completed |
NCT01407003 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1/Phase 2 | |
Completed |
NCT01127308 -
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
|
Phase 1 | |
Completed |
NCT00337610 -
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
|
Phase 3 |